Abstract 3419: TY-1091, a highly selective and potent second-generation RET inhibitor, demonstrates superior antitumor activity in multiple RET-mutant models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3419
Abstract: Proto-oncoprotein RET (rearranged during transfection) is a receptor tyrosine kinase and belongs to the cadherin superfamily. RET fusion proteins and gatekeeper mutations represent strong cancer drivers involved in the development of a variety of cancers.… read more here.
Keywords: ret; generation ret; cancer; ret inhibitor ... See more keywords
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-18-0489
Abstract: BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology.… read more here.
Keywords: generation ret; next generation; stop fretting; fretting target ... See more keywords